Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €37.22 EUR
Change Today -1.09 / -2.85%
Volume 47.0
OZT On Other Exchanges
Symbol
Exchange
OTC US
OTC US
NASDAQ GS
OTC US
Mexico
Continuous
Continuous
Frankfurt
Frankfurt
As of 1:16 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

grifols sa (OZT) Snapshot

Open
€37.89
Previous Close
€38.31
Day High
€38.00
Day Low
€37.22
52 Week High
04/15/15 - €42.80
52 Week Low
10/16/14 - €28.70
Market Cap
11.6B
Average Volume 10 Days
388.9
EPS TTM
--
Shares Outstanding
213.1M
EX-Date
12/4/14
P/E TM
--
Dividend
€0.25
Dividend Yield
1.21%
Current Stock Chart for GRIFOLS SA (OZT)

Related News

No related news articles were found.

grifols sa (OZT) Related Businessweek News

No Related Businessweek News Found

grifols sa (OZT) Details

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes plasma derivative products in the United States, Canada, Spain, rest of the European Union, and internationally. It specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation, and reagents for use in hospitals and clinics. The company operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, which include IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, and software for use in diagnostic and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by and in hospitals, such as parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

13,993 Employees
Last Reported Date: 02/26/15
Founded in 1940

grifols sa (OZT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

grifols sa (OZT) Key Developments

Grifols, S.A. Announces Audited Consolidated Revenue Results for the Fourth Quarter Ended December 31, 2014; Announces Audited Consolidated Earnings Results for the Full Year Ended December 31, 2014

Grifols, S.A. announced audited consolidated revenue results for the fourth quarter earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, net revenue of EUR 917.3 million against EUR 695.2 million a year ago. The company reported earnings results for the full year ended December 31, 2014. For the year, the company reported net revenues of EUR 3,355,384,000 against EUR 2,741,732,000 a year ago. Operating profit was EUR 857,689,000 against EUR 736,120,000 a year ago. Profit before income tax from continuing operations was EUR 589,680,000 against EUR 497,536,000 a year ago. Profit after income tax from continuing operations was EUR 467,083,000 against EUR 342,054,000 a year ago. Profit attributable to company was EUR 470,253,000 against EUR 345,551,000 a year ago. Net cash from operating activities was EUR 978,928,000 against EUR 592,011,000 a year ago. Diluted earnings per share were EUR 1.37 against EUR 1.01 a year ago. In 2014, the company completed its 2014 CAPEX plan allocating a total of EUR 251.8 million EUR 151.687 million a year ago, to expanding manufacturing facilities both in Spain and the United States, including measures designed to strengthen the Diagnostic division following the expansion of the group’s presence in the trans fusional diagnostics sector, and those aimed at the Hospital division. Adjusted EBITDA was EUR 1,074,159,000 against EUR 917,366,000 a year ago. EBITDA was EUR 1,047,161,000 against EUR 864,588,000 a year ago. Net debt was EUR 3,235.7 million. Adjusted net profit was EUR 597.9 million against EUR 450 million a year ago.

Grifols, S.A., Board Meeting, Feb 20, 2015

Grifols, S.A., Board Meeting, Feb 20, 2015. Agenda: To consider audited consolidated earnings results for the full year ended December 31, 2014.

Grifols, S.A. to Report Fiscal Year 2014 Results on Feb 26, 2015

Grifols, S.A. announced that they will report fiscal year 2014 results on Feb 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OZT:GR €37.22 EUR -1.09

OZT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $135.43 USD -1.65
Endo International PLC $84.53 USD -1.78
H Lundbeck A/S kr130.50 DKK +0.90
Hospira Inc $87.66 USD -0.07
UCB SA €61.81 EUR -1.64
View Industry Companies
 

Industry Analysis

OZT

Industry Average

Valuation OZT Industry Range
Price/Earnings 25.7x
Price/Sales 3.6x
Price/Book 4.5x
Price/Cash Flow 16.0x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GRIFOLS SA, please visit www.grifols.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.